Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...
Company
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...
Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109
China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...
Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19
Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...
Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer
China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD)...
Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors
On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation...
Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership...
Sanofi’s Sarclisa Meets Co-Primary Endpoints in Phase III IRAKLIA Study for Multiple Myeloma
French pharmaceutical giant Sanofi (NASDAQ: SNY, EPA: SAN) has announced that the Phase III IRAKLIA...
FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted...
Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio
German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...
Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments
UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co....
Roche Gains FDA 510(k) Clearance for Roche Digital Pathology Dx with VENTANA DP 600
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced an additional 510(k) clearance from the...
TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership
China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM)...
Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development
UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by...
ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products
Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The...
SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies
On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement...
MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201
Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688)...
Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...
Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis
Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA),...